ALQA Insider Trading Activity and SEC Form 4 Filings
ALQA insider trading summary
No open-market insider purchases or sales of Alliqua BioMedical, Inc. (ALQA) have been reported on SEC Form 4 in the past 12 months.
Latest ALQA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 3, 2017 | Pellegrino Pionati | See Remarks | Buy | $20K (50,000 @ $0.40) |
| Apr 3, 2017 | Joseph M Leone | Director | Buy | $10K (25,000 @ $0.40) |
| Apr 3, 2017 | David Ian Johnson | President and CEO | Buy | $100K (250,000 @ $0.40) |
| Apr 3, 2017 | Mark T Wagner | Director | Buy | $25K (62,500 @ $0.40) |
| Apr 3, 2017 | Bradford Barton | Chief Operating Officer | Buy | $30K (75,000 @ $0.40) |
| Feb 27, 2017 | Jerome B Zeldis | Director | Buy | $200K (400,000 @ $0.50) |
| Feb 27, 2017 | Celgene Corp | 10% Owner | Buy | $2.0M (4,000,000 @ $0.50) |
| Nov 9, 2015 | Brian M Posner | Chief Financial Officer | Buy | $15K (5,000 @ $3.04) |
| Nov 6, 2015 | Joseph M Leone | Director | Buy | $10K (3,500 @ $2.78) |
| Nov 6, 2015 | Jerome B Zeldis | Director | Buy | $41K (14,000 @ $2.91) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.